|
Control limit of Nitrosamines and N-nitroso compounds
|
|
2
|
501
|
July 8, 2024
|
|
Discussion on Cleaning Validation Requirements for Nitrosamines
|
|
3
|
1129
|
June 24, 2024
|
|
Tetrazole nitrosamines
|
|
1
|
304
|
June 13, 2024
|
|
Quelles Nitrosamines la Picloxidine est-elle susceptible de former?
|
|
1
|
334
|
June 12, 2024
|
|
Limit for API having two NDSRI
|
|
14
|
2569
|
June 11, 2024
|
|
Examining the Use of Surrogates in Combination with The Carcinogenic Potency Categorization Approach when Establishing Acceptable Intake Limits of N-Nitrosamine Impurities
|
|
0
|
509
|
June 9, 2024
|
|
Structuring expert review using AOPs: Enabling robust weight-of-evidence assessments for carcinogenicity under ICH S1B(R1)
|
|
0
|
291
|
June 9, 2024
|
|
Update: EFPIA workflows for Quality Risk management Jun 2024 v03
|
|
2
|
1254
|
June 4, 2024
|
|
🇨🇦 Health Canada updated the guidance and Appendix 1(March 15, 2024)
|
|
11
|
3611
|
June 3, 2024
|
|
N-nitroso-nitrofurantoin
|
|
0
|
303
|
May 31, 2024
|
|
⚙️🌎CPCA: the gestation, birth, and development -Pub
|
|
5
|
1194
|
May 31, 2024
|
|
Category 5 NDSRIs- CPCA tool
|
|
2
|
550
|
May 20, 2024
|
|
Challenges and winning strategies to develop an analytical method for Nitrosamines
|
|
0
|
753
|
May 19, 2024
|
|
Hot of the presses - New CPCA paper
|
|
1
|
436
|
May 17, 2024
|
|
Nitrosamine and NDSRIs conventional detection methods and other options
|
|
5
|
616
|
May 16, 2024
|
|
Managing the complexities of NDSRI method development: The N-nitroso propranolol case story
|
|
0
|
555
|
May 14, 2024
|
|
How to justify the absence of NDSRIs in finished product if the custom synthesis of the same NDSRIs is not possible?
|
|
1
|
843
|
May 13, 2024
|
|
Using the Carcinogenicity Potency Categorization Algorithm to Predict N-Nitrosamine Carcinogenicity -Webinar
|
|
0
|
381
|
May 13, 2024
|
|
APIC NA Risk Assessment Template
|
|
5
|
4078
|
May 11, 2024
|
|
Nitrosamine testing results
|
|
9
|
1056
|
April 18, 2024
|
|
Nitrosamines: A new systematic review
|
|
8
|
3434
|
April 13, 2024
|
|
Whether N-Nitroso Dicyclomine possible?
|
|
1
|
517
|
April 12, 2024
|
|
N-Nitroso Edoxaban Desmethyl Impurity CPCA Score
|
|
6
|
1498
|
April 8, 2024
|
|
Request for risk assessment and confirmatory testing for nortriptyline containing products
|
|
4
|
710
|
April 3, 2024
|
|
Risk Assessment Study of Nitrosamines for the API Temozolomide Industrial Process -Pub
|
|
1
|
2078
|
February 6, 2024
|
|
Antioxidant as a risk mitigation strategy
|
|
5
|
818
|
March 28, 2024
|
|
AI difference between FDA and EMA, HC and TGA
|
|
0
|
1222
|
March 22, 2024
|
|
IVACAFTOR (N-Nitroso Ivacaftor)
|
|
0
|
374
|
March 22, 2024
|
|
Application of duplex sequencing to evaluate mutagenicity -Pub
|
|
1
|
398
|
March 14, 2024
|
|
🇪🇺 OMCL Network published NDSRIs Analytical Methods
|
|
1
|
1583
|
March 11, 2024
|